ERAS
Price
$1.16
Change
-$0.01 (-0.85%)
Updated
Apr 17 closing price
Capitalization
328.59M
19 days until earnings call
STRO
Price
$0.52
Change
-$0.02 (-3.70%)
Updated
Apr 17 closing price
Capitalization
43.95M
30 days until earnings call
Ad is loading...

ERAS vs STRO

Header iconERAS vs STRO Comparison
Open Charts ERAS vs STROBanner chart's image
Erasca
Price$1.16
Change-$0.01 (-0.85%)
Volume$952.48K
Capitalization328.59M
Sutro Biopharma
Price$0.52
Change-$0.02 (-3.70%)
Volume$1.34M
Capitalization43.95M
ERAS vs STRO Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. STRO commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and STRO is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (ERAS: $1.16 vs. STRO: $0.52)
Brand notoriety: ERAS and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 56% vs. STRO: 83%
Market capitalization -- ERAS: $328.59M vs. STRO: $43.95M
ERAS [@Biotechnology] is valued at $328.59M. STRO’s [@Biotechnology] market capitalization is $43.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, both ERAS and STRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 4 TA indicator(s) are bullish while STRO’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 4 bullish, 3 bearish.
  • STRO’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, STRO is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +8.92% price change this week, while STRO (@Biotechnology) price change was -8.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

STRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($329M) has a higher market cap than STRO($43.9M). ERAS YTD gains are higher at: -53.785 vs. STRO (-71.489). ERAS has higher annual earnings (EBITDA): -151.33M vs. STRO (-186.81M). ERAS (319M) and STRO (317M) have equal amount of cash in the bank . STRO has less debt than ERAS: STRO (23.2M) vs ERAS (52.9M). STRO has higher revenues than ERAS: STRO (62M) vs ERAS (0).
ERASSTROERAS / STRO
Capitalization329M43.9M749%
EBITDA-151.33M-186.81M81%
Gain YTD-53.785-71.48975%
P/E RatioN/AN/A-
Revenue062M-
Total Cash319M317M101%
Total Debt52.9M23.2M228%
FUNDAMENTALS RATINGS
STRO: Fundamental Ratings
STRO
OUTLOOK RATING
1..100
52
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
98
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASSTRO
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 4 days ago
77%
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIRTX30.150.07
+0.23%
MFS Massachusetts Investors Tr R2
PMGJX6.45N/A
N/A
Principal MidCap Growth J
BTBFX58.08N/A
N/A
Boston Trust Asset Management
IUENX25.46N/A
N/A
JPMorgan International Focus R6
VSQRX14.91N/A
N/A
Invesco MSCI World SRI Index R

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-0.85%
RVMD - ERAS
54%
Loosely correlated
+1.55%
XNCR - ERAS
52%
Loosely correlated
+1.89%
KYMR - ERAS
52%
Loosely correlated
+3.80%
IMNM - ERAS
50%
Loosely correlated
+10.32%
ELVN - ERAS
50%
Loosely correlated
+2.86%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with ALGS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then ALGS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
-2.85%
ALGS - STRO
44%
Loosely correlated
+2.41%
TRDA - STRO
43%
Loosely correlated
+3.44%
ERAS - STRO
43%
Loosely correlated
-0.85%
ATXS - STRO
41%
Loosely correlated
+1.51%
TCRX - STRO
41%
Loosely correlated
+10.77%
More